Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JS207 (PD-1/VEGF bispecific antibody) combination therapy in driver-gene-positive advanced NSCLC after TKI failure
CTR20250764Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2025
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JS207 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started May 2025; status: active.
02
Drugs
JS207
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250764.